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Abstract
Organic anion transporting polypeptides (Oatps/OATPs) form a growing gene superfamily and mediate transport of a wide spectrum of
amphipathic organic solutes. Different Oatps/OATPs have partially overlapping and partially distinct substrate preferences for organic solutes
such as bile salts, steroid conjugates, thyroid hormones, anionic oligopeptides, drugs, toxins and other xenobiotics. While some Oatps/OATPs
are preferentially or even selectively expressed in one tissue such as the liver, others are expressed in multiple organs including the blood–
brain barrier (BBB), choroid plexus, lung, heart, intestine, kidney, placenta and testis. This review summarizes the actual state of the rapidly
expanding OATP superfamily and covers the structural properties, the genomic classification, the phylogenetic relationships and the
functional transport characteristics. In addition, we propose a new species independent and open ended nomenclature and classification
system, which is based on divergent evolution and agrees with the guidelines of the Human Genome Nomenclature Committee.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Organic anion transporting polypeptides (rodents: Oatps;
human: OATPs) are a group of membrane solute carriers
with a wide spectrum of amphipathic transport substrates
[1,2]. Although some important members of this transporter
superfamily are selectively expressed in rodent and human
livers, where they are involved in the hepatic clearance of
albumin-bound compounds from portal blood plasma [3],
most Oatps/OATPs are expressed in multiple tissues includ-
ing the blood–brain barrier (BBB), choroid plexus, lung,
heart, intestine, kidney, placenta and testis [4]. Only a
portion of the Oatps/OATPs so far identified has been
characterized in detail on the functional, structural and
genomic levels. However, initial studies with individual
Oatps/OATPs indicate that many members of this trans-
porter family represent polyspecific organic anion carriers
with partially overlapping and partially distinct substrate
preferences for a wide range of amphipathic organic solutes
including bile salts, organic dyes, steroid conjugates, thyroid
hormones, anionic oligopeptides, numerous drugs and other
xenobiotic compounds [1,2,5]. This overview summarizes
the structural properties, genomic classification, phyloge-
netic relationships and functional transport characteristics of
the currently known rodent and human Oatps/OATPs.
Furthermore, the article proposes a new nomenclature
system that is based on divergent evolution, uses function-
ally based root symbols, is species independent and open
ended, and thus could help to end the current chaotic
nomenclature status and to prevent future confusions and
misunderstandings regarding the clear identification of indi-
vidual members of the OATP-superfamily of membrane
transporters.
2. Classification of Oatp/OATP genes
Currently, 11 rat, 8 mouse and 9 human Oatps/OATPs
have been identified. Their genes are currently classified
within the solute carrier family 21A (rodents: Slc21a;
humans: SLC21A) of the human (http://www.gene.ucl.ac.
uk/) and mouse (http://www.informatics.jax.org/) genome
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nomenclature databases. As it can be seen from Table 1, with
the exception of OATP8 (SLC21A8), the trivial names for
individual proteins do not correspond to the continuous
numbering (based on the chronology of protein identifica-
tion) within the Slc21a/SLC21A classification. Furthermore,
for many rat/mouse Oatp genes no orthologous human
OATP genes have so far been identified indicating no strict
one to one relationship between rodent Oatps and human
OATPs [4]. In addition, different names have been coined on
the protein level, which has led to some confusion in the
differentiation between certain individual rodent and human
Oatps/OATPs, as exemplified in a recent publication where
the regulation of the rat/mouse Oatp2 has been erroneously
attributed to the non-orthologous human OATP2 [6]. Hence,
for clear-cut identification of a specific gene product, it has
been suggested to continue with the numbering of rodent
Oatps, to adopt provisionally the alphabetic designation of
human OATPs and to always add the corresponding Slc21a/
SLC21A gene symbol in parenthesis [4,5]. However, since
this nomenclature does still not conform to a species in-
dependent and open-ended classification, a more definitive
classification system based on divergent evolution (amino
acid sequence identities) would be advantageous and is
proposed below (see Section 7).
3. Structural characteristics of Oatps/OATPS
Based on hydropathy analysis, all Oatps/OATPs contain
12 transmembrane (TM) domains as indicated in Fig. 1 for
rat Oatp1 (Slc21a1) [7]. However, it is important to realize
that the predicted 12 TM domain model has not been proven
experimentally for any Oatp/OATP so far identified. Com-
mon structural features among all Oatps/OATPs include (1)
the large extracellular domain between TMs 9 and 10
(extracellular loop 5), which contains many conserved
cysteine residues that resemble the zinc finger domains of
DNA binding proteins [8], (2) the N-glycosylation sites in
extracellular loops 2 and 5 [9], and (3) the OATP ‘‘super-
family signature’’ (see Fig. 3) at the border between extrac-
ellular loop 3 and TM domain 6. Conserved amino acids are
preferentially found in TM domains 2 to 6, in extracellular
loops 1, 3, 5 and in intracellular loops 1, 2, 4 and 5 (Fig. 1).
Conserved charged amino acids are located predominantly
at the boundaries of the TM domains, especially on the
Table 1
Oatp/OATP gene classification as implemented by the human and mouse
gene nomenclature committees
Name Alias Human
gene name
Rat gene
name
Mouse
gene name
Oatp1 Oatp – Slc21a1 Slc21a1
PGT hPGT (man),
rPGT (rat),
mPGT (mouse)
SLC21A2 Slc21a2 Slc21a2
OATP-A OATP, OATP1 SLC21A3 – –
OAT-K1 – Slc21a4 –
Oatp2 – Slc21a5 Slc21a5
OATP-C LST-1, OATP2,
OATP6
SLC21A6 – –
Oatp3 – Slc21a7 Slc21a7
OATP8 LST-2 SLC21A8 – –
OATP-B OATP-RP2 (man),
moat1 (rat), Oatp9
SLC21A9 Slc21a9 –
Oatp4 rlst-1 (rat), mlst-1
(mouse)
– Slc21a10 Slc21a10
OATP-D OATP-RP3 (man),
Pgt2 (rat), MJAM
(mouse), Oatp11
SLC21A11 Slc21a11 Slc21a11
OATP-E OATP-RP1 (man),
oatpE (rat), Oatp12
SLC21A12 Slc21a12 –
Oatp5 – Slc21a13 Slc21a13
OATP-F OATP-RP5 (man),
BSAT1 (rat), Oatp2
(mouse), Oatp14
SLC21A14 Slc21a14 Slc21a14
OATP-J OATP-RP4 SLC21A15 – –
The aliases in bold will be used in this review for the rat and mouse species
if available.
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Fig. 1. Predicted 12 transmembrane domain model of rat Oatp1. Conserved amino acids (see Fig. 2) are indicated in black. Conserved and charged amino acids
(D, E, K, R) are given in gray, and conserved cysteines (C) are marked with asterisks. Three potential N-glycosylation sites (Y) are present on extracellular
protein loops. The OATP superfamily signature (see Fig. 3) is indicated at the border of the extracellular loop 3 and the transmembrane domain 6.
B. Hagenbuch, P.J. Meier / Biochimica et Biophysica Acta 1609 (2003) 1–182
Fig. 2. Multiple alignment of human, rat and mouse Oatps/OATPs. The program PILEUP from the GCG software package (Genetics Computer Group, Madison, WI) [12] was used to align the amino acid sequences
of the 18 Oatps/OATPs for which functional transport data are available. Splice variants such as OAT-K2 and rlst-1 were not considered. Positions of the respective amino acid residues are listed for the individual
proteins. Note that for some amino acid sequences the alignment does not start at position 1. The consensus sequence (Con) contains amino acid residues that are conserved in at least 15 Oatps/OATPs.
Transmembrane domains were estimated with the help of the TMHMM program (http://www.cbs.dtu.dk/services/TMHMM-2.0/) [13]. They are indicated with dark gray bars and numbered continuously in roman
numbers.
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cytoplasmic side of the membrane. Within the membrane
the only charged amino acids conserved are found in TM
domains 2, 11 and 12. The physiological importance of
these charged amino acid residues for transmembrane sub-
strate transport will have to be determined by site-directed
mutagenesis.
3.1. Multiple amino acid sequence alignment and evolu-
tionary relationship
Fig. 2 compares the amino acid sequences of 18 mem-
bers of the OATP superfamily. All cloned proteins contain
between 643 (rat, mouse and human prostaglandin trans-
porters (PGTs); Slc21a2/SLC21A2) and 722 (OATP-E;
SLC21A12) amino acids [4,10,11]. Altogether, 57 amino
acid residues have been conserved through all 18 family
members. They include 15 glycine, 11 cysteine, 8 proline, 5
tyrosine and 4 tryptophan residues. The glycine and proline
residues are important for the protein structure. Glycine has
no side chain and gives the polypeptide a much greater
flexibility than other residues, whereas proline poses more
rigid constrains on the rotational mobility and, thus, stabil-
izes the tertiary structure of the protein backbone. The
conserved cysteine residues are concentrated in the large
extracellular loop between TM domains 9 and 10 and are
responsible for the supposed zinc finger motif of the Oatps/
OATPs [8]. The physiologic significance of the latter is
unknown, but it is interesting to note that a portion of the rat
prostaglandin transporter rPGT [11] has first been isolated
as the DNA-binding protein ‘‘matrin F/G’’ [8], and that
several Oatp-related proteins in C. elegans and D. mela-
nogaster are postulated to represent also zinc finger DNA-
binding proteins. Since the sequence of cysteine residues
resembles that of the class 2 or C4 type zinc finger domains
that is also found in steroid hormone receptors and since
Oatps/OATPs mediate transport of steroid hormones and
their conjugates (see below), it is tempting to speculate that
this region could be involved in substrate recognition and/or
binding.
3.2. Evolutionary relationship
Interestingly, conserved amino acids also include four
tryptophan residues, three of which form part of the highly
conserved consensus sequence D-X-RW-(I,V)-GAWW-X-
G-(F,L)-L at the border of extracellular loop 3 and TM
domain 6 (Figs. 1–3). If this OATP ‘‘superfamily signature’’
was used to search the Genbank database for related
sequences, a total number of 39 Oatp/OATP-related proteins
were identified including all known Oatps/OATPs, two new
Oatps from B. taurus and R. erinacea and 12 proteins of
unknown function from C. elegans and D. melanogaster
(Fig. 3). However, no bacterial or yeast proteins with
significant homologies were found. Intriguingly, all these
Oatp/OATP-related proteins contain, in addition to the
‘‘superfamily signature’’, the conserved cysteine residues
in the extracellular loop between TMs 9 and 10 (data not
shown), thus supporting further the evolutionary relation-
ship of the various proteins. However, whether all Oatp/
OATP-related proteins including the superfamily members
of C. elegans and D. melanogaster represent multispecific
membrane transporters remains to be verified.
The overall amino acid sequence identities between all
Oatp/OATP-related proteins summarized in Fig. 3 vary
between 24% and 82% (calculated by BESTFIT). Hence,
based on this amino acid sequence identities, all Oatp/
OATP-related proteins form a gene superfamily that spans
a wide range of animal species. Considering only mamma-
lian Oatps/OATPs, the amino acid sequence identities vary
between 31% and 82% (Table 2). If one arranges these
amino acid sequence identities into groups of decreasing
identities, it becomes evident that individual proteins cluster
into families (z 40% identity) and subfamilies (z 60%
Fig. 3. Multiple alignment of the OATP-superfamily signature. The
consensus sequence was used to BLAST the GenBank database. Besides
the known mammalian OATPs several potential organic anion transporters
from C. elegans, D. melanogaster, B. taurus and R. erinacea were
identified and are indicated with their protein accession numbers.
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identities) as it has been previously shown for drug metab-
olizing enzymes [14–16]. Interestingly, the members of the
OATP3-family (i.e. rOatp11, mOatp11, OATP-D) show the
highest conservation with amino acid identities of 97% and
98% among rat, mouse and human proteins (Table 2). The
clustering of individual Oatps/OATPs into families and
subfamilies is further evident from the phylogenetic tree
(Fig. 4). Thereby, the proteins with the broadest spectrum of
amphipathic transport substrates are clustered in the large
OATP1 family. These OATP1-family members are thought
to be part of the overall body detoxification system and help
to remove potentially toxic endo- and xenobiotics from the
systemic circulation (e.g. drug uptake into the liver) [1].
Although the exact physiological functions of most Oatps/
OATPs remain to be elucidated, most Oatps/OATPs of
families 2–4 have narrower substrate specificities (e.g.
OATP-B, OATP-E) and may serve more specific functions
in selected organs such as for example thyroid hormone
transport in various peripheral organs [18] or steroid and
steroid metabolite transport in adrenal gland and placenta
[19,20]. Thus, the functional diversity of the OATP super-
family could be very similar to the CYP450 superfamily
where only families 1–4 are involved in metabolism and
detoxification of drugs and environmental chemicals,
whereas the members of the other families catalyze specific
pathways in the cholesterol, prostacyclin and/or steroid
metabolism [16].
3.3. Chromosomal localization
Based on the available human genome data, all human
OATP genes could be mapped on the genomic level and
are located on chromosomes 3 (SLC21A2), 8 (SLC21A15),
11 (SLC21A9), 12 (SLC21A14, SLC21A8, SLC21A6
and SLC21A3 in this order), 15 (SLC21A11) and 20
(SLC21A12). The human OATP1 family members are not
only located all on chromosome 12 but are clustered at
12p12 on a stretch of approximately 700,000 bp. The
smallest gene is SLC21A14 (OATP-F) and covers about
58,000 bp followed by SLC21A3 (OATP-A 66,000 bp),
SLC21A6 (OATP-C 98,000 bp) and SLC21A8 (OATP8
101,000 bp). Between SLC21A8 and SLC21A6 a pseudo-
gene of approximately 172,000 bp can be found. This type
of clustering indicates that these OATPs have arisen
through gene duplications of an ancestral gene. Given
almost identical lengths of the respective exons in the
different OATPs [21], it is tempting to speculate that the
newer a gene, the longer the intronic sequences. This would
suggest that OATP-F represents the oldest OATP in this
family and that the pseudogene represents the last addition.
This assumption is supported by the recent identification of
the first and so far only OATP in the liver of the little skate
that shares the highest amino acid identity with OATP-F
and transports a wide range of different compounds [22].
Sequencing of the mouse genome is also very advanced and
Table 2
Amino acid sequence identities among the different members of the OATP superfamily
Amino acid sequence identities were calculated using the GCG program BESTFIT. Identities above 60% are printed in white on black, identities between 40% and
60% are printed in white on gray while identities below 40% are printed in black on white. The 28 Oatps/OATPs presented in Table 1 are shown.
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huge continuous clusters can be compared to the human
syntenic regions. Interestingly, all mouse OATP1 family
members can be located on an approximately 800,000 bp
cluster on mouse chromosome 6 (including Slc21a1, which,
using fluorescence in situ hybridization, has previously
been mapped to chromosome X [23]) in a similar order
Fig. 4. Phylogenetic tree of the mammalian Oatps/OATPs. The phylogenetic tree was calculated using GCG programs PILEUP, DISTANCES and GROWTREE and
visualized using the program TreeView [17]. The individual families contain proteins with amino acid sequence identities of z 40%. Subfamilies are indicated
by capital letters and contain proteins with amino acid sequence identities of z 60%.
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as the human genes (Slc21a14, Slc21a10, Slc21a13,
Slc21a5, Slc21a1 and Slc21a7). This comparison clearly
suggests that there is no single orthologue of the human
OATP-A in the mouse (Oatp1, Oatp2, Oatp3 and Oatp5)
and no single orthologue of the mouse Oatp4 in man
(OATP-C and OATP8). All the other so far known mouse
Oatp genes can also be mapped to syntenic chromosomes in
man.
4. Functional properties of Oatps/OATPs
4.1. Broad spectrum of transported substrates
Originally, Oatp1 has been cloned as a sodium-independ-
ent bromosulfophthalein (BSP) and taurocholate uptake
system of rat liver [7,24,25]. However, later it has been
shown that Oatp1 can mediate transmembrane transport of a
wide range of amphipathic organic compounds including
bile salts [26–28], steroid hormones and their conjugates
[27–31], thyroid hormones [32], and even organic cations
like N-(4,4-azo-n-pentyl)-21-deoxy-ajmalinium [29,33] and
to a lesser degree also N-methyl-quinine and rocuronium
[33] (Table 3). Such a broad and partially overlapping
substrate specificity has also been documented for other
Oatps/OATPs (Table 3). In addition to endogenous and
exogenous amphipathic compounds, Oatps/OATPs can
mediate transport of numerous drugs including the endo-
thelin receptor antagonist BQ-123 [28], the thrombin inhib-
itor CRC-220 [34], the opioid receptor agonists [D-
penicillamine 2,5]enkephalin (DPDPE) and deltorphin II
[35], the angiotensin-converting enzyme inhibitors enalapril
and temocaprilat [36,37], the HMG-CoA reductase inhibitor
pravastatin [38] and the antihistamine fexofenadine [39]
(Table 3). Therefore, these multispecific transporters (espe-
cially the members of the OATP1A and 1B subfamilies (Fig.
4, Table 3)) are important drug transporters that, together
with the P-glycoproteins and the multidrug resistance asso-
ciated proteins (Mrps), seem to play an important role in
overall drug absorption and drug disposition. Since not all
substrates have been tested with all Oatps/OATPs, only a
few ‘‘specific’’ substrates could be identified so far (e.g.
gadoxetate and dinitrophenyl-glutathione (DNP-SG) for
Oatp1, bilirubin and bisglucuronosyl bilirubin for OATP-
C, CCK-8 for the rat Oatp4 and the human OATP8).
However, differences in substrate transport have been docu-
mented with respect to apparent affinities: Oatp2 is a high
affinity digoxin transporter (apparent Km= 0.24 AM) [40],
OAT-K1 a high affinity methotrexate carrier (apparent
Km= 1 AM) [41] and OATP-F a high affinity T4 and rT3
transporter [21].
What are the chemical/structural requirements for a
compound to be transported by Oatps/OATPs? So far
no systematic studies have been performed to investigate
this but from the data summarized in Table 3, it can be
concluded that in general Oatp/OATP substrates are
mainly anionic amphipathic molecules with high molec-
ular weight (>450) that under normal physiological con-
ditions (with few exceptions as e.g. gadoxetate) are bound
to proteins (mostly albumin). Or more specifically, com-
pounds with a steroid nucleus (e.g. bile salts, steroid
hormones and their conjugates) or small linear and cyclic
peptides are likely candidates to be transported by certain
Oatps/OATPs. These are also the attributes of compounds
that are mainly excreted into bile while products that are
normally excreted into urine are represented by small and
mainly hydrophilic compounds with low protein binding
and are known substrates of the organic anion (OATs) and
organic cation transporters (OCTs) [42,43]. However, for
a more exact determination of the structural requirements
of Oatp/OATP substrates, additional experiments are re-
quired.
4.2. Transport mode
Unlike the Na+/taurocholate cotransporting polypeptide
(Ntcp/NTCP), which couples downhill sodium import to
uphill bile salt uptake [75,76], it is well accepted that Oatps/
OATPs represent sodium-independent bile salt and organic
anion transport systems [7,40,57,64]. Their transport mech-
anism appears to be anion exchange as evidenced by
bidirectional transmembrane BSP transport in Oatp1
expressing HeLa cells [25] and by Oatp1-mediated taur-
ocholate/HCO3 exchange [44]. The driving force for Oatp/
OATP-mediated transport has not been investigated in detail
for all transporters, but for Oatp1 and Oatp2 there exists
experimental evidence that intracellular GSH plays an
important role. Oatp1-expressing oocytes showed increased
[3H]glutathione (GSH) efflux and a stoichiometry of GSH/
taurocholate exchange of 1:1, indicating that Oatp1 partic-
ipates in overall GSH efflux from hepatocytes [45]. Hence,
physiologic GSH efflux could represent an important driv-
ing force for Oatp1-mediated substrate uptake into hepato-
cytes as well as into choroid plexus epithelial cells [77].
Similar to Oatp1, Oatp2-mediated taurocholate transport
was also stimulated by high intracellular GSH concentra-
tions [78]. However, simultaneous changes of the extrac-
ellular GSH concentration did not affect Oatp2 mediated
substrate transport suggesting that intracellular GSH rather
than the in to out GSH gradient is important for Oatp2
mediated taurocholate uptake [78]. Additional evidence for
an asymmetric transport mechanism of Oatp2 was derived
from the observation that Oatp2 expressing oocytes were
not able to accumulate radiolabeled DNP-SG from the
extracellular medium, whereas high intracellular concentra-
tions of DNP-SG stimulated Oatp2-mediated taurocholate
uptake [78]. If we assume such an asymmetric transporter
mode for all Oatps/OATPs, intracellular GSH may be also
important for OATP8-mediated transport although extracel-
lular GSH did not cis-inhibit OATP8-mediated BSP uptake
nor was it transported into OATP8 expressing HEK293 cells
[74].
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Table 3
Molecular characteristics of the members of the OATP superfamily
Transporter Sizea Substrates (Km value) Main location References
Rat Oatps
Oatp1 (Slc21a1) 670 Bile salts: cholate (54 AM), glycocholate (54 AM),
taurocholate (19–50 AM), TCDCA (7 AM),
TUDCA (13 AM), sulfotaurolithocholate (6 AM).
Hormones and their conjugates: aldosterone (15 nM),
cortisol (13 AM), DHEAS (5 AM), E217hG (3–20 AM),
E-3-S (5–12 AM), T3, rT3, T4. Eicosanoids:
LTC4 (270 nM). Peptides: BQ-123 (600 AM), CRC220
(30–57 AM), deltorphin II (137 AM), DPDPE (48 AM),
GSH. Drugs: dexamethasone, enalapril (214 AM),
fexofenadine (32 AM), gadoxetate (3.3 mM), ouabain
(1.7–3 mM), pravastatin (30 AM), temocaprilat (47 AM).
Other organic anions: monoglucuronosyl bilirubin, BSP
(1–3 AM), BSP-DNP-SG (408 AM), E3040 glucuronide.
Organic cations: APD-ajmalinium, N-methylquinidine,
rocuronium. Toxins: ochratoxin A (17–29 AM).
mRNA: liver, kidney,
brain, lung, retina, skeletal
muscle, proximal colon
[7,25–29,
31–39,44–49]
Protein: liver, kidney,
choroid plexus (?)
rPGT (Slc21a2) 643 Eicosanoids: 6-ketoprostaglandine F1a (6 AM),
prostaglandine D2, prostaglandine E1 (70 nM),
prostaglandine E2 (94 nM), prostaglandine E2a
(104 nM), thromboxane B2 (423 nM).
Ubiquitously [10,11]
OAT-K1/2 (Slc21a4) 669/498 Bile salts: taurocholate (10/31 AM). Hormones
and their conjugates: DHEAS (8/8 AM), E217hG
(35/45 AM), E-3-S (12/15 AM), T3 (44/25 AM),
T4 (20/12 AM). Eicosanoids: prostaglandine E2.
Drugs: methotrexate (1–2 AM), zidovudine
(64/76 AM). Other organic anions: folate. Toxins:
ochratoxin A (6/17 AM).
Protein: kidney [41,50–52]
Oatp2 (Slc21a5) 661 Bile salts: cholate (46 AM), glycocholate (40 AM),
taurocholate (35 AM), TCDCA (12 AM), TUDCA
(17 AM). Hormones and their conjugates: DHEAS
(17 AM), E217hG (3 AM), E-3-S (11 AM), T3 (6 AM), T4
(7 AM). Peptides: BQ-123 (30 AM), DPDPE (19 AM),
Leu-enkephalin. Drugs: biotin, digoxin (240 nM),
fexofenadine (6 AM), ouabain (470 AM), pravastatin
(38 AM). Organic cations: APD-ajmalinium, rocuronium.
mRNA: liver, kidney,
brain, retina
[28,33,35,39,
40,53–55]
Protein: liver, BBB,
choroid plexus, retina
Oatp3 (Slc21a7) 670 Bile salts: cholate (3 AM), glycocholate (15 AM),
glycodeoxycholate (4 AM), GCDCA (6 AM), GUDCA
(5 AM), taurocholate (18–30 AM), taurodeoxycholate
(6 AM), TCDCA (7 AM), TUDCA (7 AM). Hormones and
their conjugates: DHEAS (162 AM), E217hG (39 AM),
E-3-S (268 AM), T3 (7 AM), T4 (5 AM). Eicosanoids:
LTC4, prostaglandine E2 (35 AM). Peptides: BQ-123
(417 AM), DPDPE (137 AM). Drugs: digoxin,
fexofenadine, ouabain (1.6 mM). Other organic anions:
BSP (8 AM). Organic cations: rocuronium.
mRNA: retina, brain, kidney,
liver, small intestine
[53,56–58]
Protein: jejunum,
choroid plexus (?)
Oatp9 (Slc21a9) 682 Bile salts: taurocholate (18 AM). Eicosanoids: LTC4
(3 AM), prostaglandine D2 ( 36 nM), prostaglandine
E1, prostaglandine E2, thromboxane B2. Drugs: iloprost.
mRNA: liver, lung, heart,
brain, retina, kidney
[59]
Oatp4 (Slc21a10) 687 Bile salts: taurocholate (27 AM). Hormones and their
conjugates: DHEAS (5 AM), E217hG (32 AM), E-3-S
(37 AM), T3, T4. Eicosanoids: LTC4 (7 AM), prostaglandine
E2 (13 AM). Other organic anions: BSP (1 AM). Toxins:
mycrocystin, phalloidinb.
Protein: liver, eye [58,60–62]
Oatp11 (Slc21a11) 710
Oatp12 (Slc21a12) 722 Bile salts: taurocholate. Hormones: T3.
Eicosanoids: prostaglandine E2.
[18]
(continued on next page)
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4.3. Tissue distribution
The tissue distribution of Oatps/OATPs has been studied
using different techniques. Consistent with their potential
role in detoxification processes, Oatps/OATPs are expressed
in various tissues as demonstrated for example by RT-PCR
techniques in normal rat [79] and human tissues as well as in
human cancer cell lines [4]. Certain transporters show a
more restricted tissue expression pattern (e.g. Oatp1, Oatp2,
Oatp3, Oatp4, OATP-A, OATP-C, OATP8 and OATP-F)
Transporter Sizea Substrates (Km value) Main location References
Rat Oatps
Oatp5 (Slc21a13) 670 mRNA: kidney Genbank:
AF053317
Oatp14 (Slc21a14) 716 mRNA: brain [63]
Human OATPs
hPGT (SLC21A2) 643 Eicosanoids: prostaglandine D2, prostaglandine
E1, prostaglandine E2, prostaglandine E2a,
thromboxane B2.
Ubiquitously [10]
OATP-A (SLC21A3) 670 Bile salts: cholate (93 AM), glycocholate,
taruocholate (60 AM),TCDCA, TUDCA
(19 AM). Hormones and their conjugates:
DHEAS (7 AM), E217hG, E-3-S (59 AM),
T3 (7 AM), rT3, T4 (8 AM). Eicosanoids:
prostaglandine E2. Peptides: BQ-123, CRC220,
deltorphin II (330 AM), DPDPE (202 AM).
Drugs: chlorambuciltaurocholate, fexofenadine
(6 AM), Gd-B 20790, ouabain (5.5 mM). Other
organic anions: BSP (20 AM). Organic cations:
APD-ajmalinium, N-methylquinine (26 AM),
N-methylquinidine (5 AM), rocuronium. Toxins:
microcystin.
mRNA: brain, kidney,
liver, lung, testis
[1,5,18,33,35,
39,62,64–68]
Protein: brain, liver
OATP-C (SLC21A6) 691 Bile salts: cholate (11 AM), glycocholate,
taurocholate (10–34 AM). Hormones and their
conjugates: DHEAS (22 AM), E217hG (8–10 AM),
E-3-S (13 AM), T3 (3 AM), T4 (3 AM). Eicosanoids:
LTC4, LTE4, prostaglandine E2, thromboxane B2.
Peptides: BQ-123, DPDPE. Drugs: benzylpenicillin,
methotrexate, pravastatin (14–35 AM), rifampicin
(13 AM). Other organic anions: bilirubin,
monoglucuronosyl bilirubin (100 nM),
bisglucuronosyl bilirubin (300 nM), BSP
(100–300 nM). Toxins: microcystin, phalloidinb.
Protein: Liver [4,5,38,62,69–73]
OATP8 (SLC21A8) 702 Bile salts: glycocholate, taurocholate (6 AM). Hormones
and their conjugates: DHEAS, E217hG (5 AM), E-3-S,
T3 (6 AM), T4. Eicosanoids: LTC4. Pepdites: BQ-123,
CCK-8 (11 AM), deltorphin II, DPDPE. Drugs: digoxin,
methotrexate (25 AM), ouabain, rifampicin (2 AM). Other
organic anions: monoglucuronosyl bilirubin (500 nM),
BSP (0.4–3 AM). Toxins: microcystin, phalloidinb.
Protein: liver [5,61,62,69,72–74]
OATP-B (SLC21A9) 709 E-3-S (6 AM), DHEAS, benzylpenicillin,
BSP (0.7 AM).
mRNA: liver, placenta,
spleen, lung,
kidney, heart, ovary,
small intestine, brain
[4,5]
Protein: liver, placenta
OATP-D (SLC21A11) 710 E-3-S, prostaglandine E2, benzylpenicillin. Ubiquitously [4]
OATP-E (SLC21A12) 722 Taurocholate (15 AM), E-3-S, E217hG, T3 (1 AM),
rT3, T4, prostaglandine E2.
Ubiquitously [4,18]
OATP-F (SLC21A14) 712 E217hG, E-3-S, T3, rT3 (130 nM), T4 (90 nM), BSP. Protein: brain, testis [21]
Abbreviations: APD-ajmalinium: N-(4,4-azo-n-pentyl)-21-deoxyajmalinium; BSP: bromosulfophthalein; BSP-SG: gluthathione-conjugated BSP; DNP-SG:
dinitrophenyl-glutathione; CCK8: cholecystokinin-8; DHEAS: dehydroepiandrosterone-sulfate; DAMGO: D-Ala2,N-Me-Phe4,Gly5-ol]-Enkephalin; DPDPE:
[D-Pen2,5]-Enkephalin; E-3-S: estrone-3-sulfate; E217hG: estradiol-17h-glucuronide; GCDCA, glycochenodeoxycholate; Gd-B 20790, gadolinium derivative;
GUDCA, glycoursodeoxycholate; TCDCA, taurochenodeoxycholate; TUDCA, tauroursodeoxycholate.
a Amino acids.
b Unpublished own observation.
Table 3 (continued )
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while others can be detected in almost every tissue that has
been investigated (e.g. Oatp9, OATP-B, OATP-D and
OATP-E). This indicates that some Oatps/OATPs have
organ-specific functions while others might be involved in
more housekeeping functions.
4.3.1. Liver
In rat (Oatp1, Oatp2 and Oatp4) and human liver (OATP-
B, OATP-C and OATP8) all Oatps/OATPs are expressed at
the sinusoidal (basolateral) plasma membrane where they
are responsible for uptake and elimination of a wide variety
of amphipathic endo- and xenobiotics (Table 3). Rifamycin
SV and rifampicin, two structurally related antibiotics that
are mainly used in the treatment of tuberculosis, have been
shown to induce hyperbilirubinemia and to reduce hepatic
elimination of BSP. In recent studies [72,80], the effect of
these antibiotics was tested on Oatp/OATP-mediated trans-
port and it could be demonstrated that rifamycin is a potent
inhibitor of rat Oatp1 and Oatp2 as well as of all human
liver OATPs with Ki values in the low micromolar range
while rifampicin mainly inhibits rat Oatp2 and human
OATP8 and to a lesser degree also OATP-C [72,80]. These
results have important implications for drug development
and drug therapy because Oatps/OATPs can play an impor-
tant role in the hepatic first pass clearance of numerous
drugs [27,81]. Therefore, coadministration of a specific
OATP-inhibitor could be used to increase the oral bioavail-
ability of drugs that otherwise have a high Oatp/OATP-
mediated first pass elimination. On the other hand, induction
of Oatp/OATP gene expression (e.g. by rifampicin via the
PXR receptor, see below) could increase the first pass
elimination of drugs that are less efficient Oatp/OATP
substrates and decrease their bioavailability to therapeuti-
cally inefficient plasma concentrations. Furthermore, ad-
verse drug reactions such as decreased drug efficacy or
even therapeutic failure of an intrahepatically active drug
(e.g. pravastatin) could be due to coadministration of an
Oatp/OATP inhibitor. Thus, inhibition of liver Oatps/OATPs
that transport a wide spectrum of compounds (Table 3) may
have important consequences for overall bioavailability and
toxicity of xenobiotics and should be considered during
drug development.
4.3.2. Brain
Certain drugs have to be transported into and toxic waste
products have to be eliminated from the brain. These
compounds need to be transported either across the BBB
or the blood cerebrospinal fluid barrier. In both epithelial
layers, Oatps/OATPs have been identified. At the BBB, rat
Oatp2 and human OATP-A are both expressed in endothe-
lial cells where they could mediate efflux of metabolites (e.g
glucuronidates, GHS-conjugates or sulfates) [82] and/or
uptake of drugs such as opioid peptides [35]. These in vitro
predictions were confirmed by in vivo experiments using
Mdr1a knockout and wild-type mice where transport of the
delta opioid receptor agonist DPDPE was studied using a
brain perfusion technique [83]. Due to Mrd1a mediated
efflux, DPDPE exhibited poor BBB permeability in wild-
type mice while in the Mdr1a knockout mice uptake of
DPDPE could readily be determined, suggesting that Oatp2
is responsible for saturable uptake of DPDPE and poten-
tially other opioid peptides across the BBB into the brain.
Similarly, the brain level ratio between Mdr1a-deficient and
normal mice was elevated for numerous compounds includ-
ing the high affinity Oatp2 substrate digoxin [84]. In
addition, efflux of estradiol-17h-glucuronide across the rat
BBB could be mainly inhibited by digoxin, supporting a
major role of Oatp2 for estradiol-17h-glucuronide efflux
[85].
In the rat choroid plexus epithelium two Oatps have been
localized. Oatp2 is expressed at the basolateral membrane
[77] while at the apical membrane Oatp1 was identified
[86,87]. However, since the antibody used was raised
against the C-terminal end and also recognizes Oatp3, it
could well be that Oatp3 is expressed in the apical mem-
brane of choroid plexus. Actually, there is additional indirect
evidence for Oatp3 expression at the choroid plexus. Using
quantitative RT-PCR, mRNA for Oatp3 was readily detected
in rat brain while no signal was obtained for Oatp1 [79].
Furthermore, the dichotomous development proposed for
Oatp1 in the liver and the choroid plexus, which was
examined using the same antibody [88], could be easily
explained with the presence of different proteins in liver
(Oatp1) and brain (Oatp3). And finally, while in the liver
both Oatp1 as well as Oatp2 are expressed in the same
basolateral plasma membrane, in the small intestine, Oatp3
is expressed in the apical membrane [57]. Functionally, the
two Oatps can account for transepithelial secretion of GSH
and efficient removal of LTC4 from the cerebrospinal fluid
[87] but also for transepithelial uptake of thyroid hormones
into the brain.
The recently characterized human OATP-F is a high
affinity thyroxine and reverse triiodo-thyrosine transporter
(Table 3) and is selectively expressed in brain and to a lesser
degree also in testis [21] where it may play an important role
in the local disposition of iodothyronines. Based on North-
ern blot analysis, OATP-F is expressed in various brain
regions; however, its exact cellular localization remains to
be determined.
4.3.3. Kidney
In the kidney several Oatps/OATPs have been identified
at the mRNA level (Oatp1, Oatp2, Oatp5, OAT-K1/2,
OATP-A, OATP-B, OATP-D and OATP-E); however, at
the protein level only Oatp1 [89] and OAT-K1/2 [51,90]
have been identified. Using an antibody against the C-
terminal end, which also recognizes Oatp3 (see above),
Oatp1 was identified at the apical plasma membrane in
the S3 segment of the proximal tubule [89]. Quantitative
RT-PCR results confirmed the presence of Oatp1 in renal
RNA while OATP3 was not detected [79]. Functionally,
Oatp1 could be responsible for reabsorption of organic
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compounds that are freely filtered, such as estradiol-17h-
glucuronide (see also below) [91], or important for the
secretion of certain organic compounds that are taken up
into proximal tubular cells across the basolateral membrane.
OAT-K1 is selectively expressed at the apical plasma
membrane of proximal tubular epithelial cells [90]. As a
high affinity methotrexate transporter, it could be involved
in the urinary secretion of this drug and thus protect renal
cells [52]. Together with a splice variant, OAT-K2, which is
also exclusively expressed in the kidney, these multispecific
organic anion transporters seem to contribute to the renal
secretion and/or reabsorption of hydrophobic anionic com-
pounds [51]. Interestingly, these two proteins are so far
specific for the rat since no orthologues have been identified
in mice.
Oatp5 is another kidney-specific Oatp since its mRNA
has not been detected in any other tissue [79]. Unfortu-
nately, so far no functional data are available and the
physiological role of Oatp5 is still unknown.
4.3.4. Placenta
Bile acids that are synthesized in utero by the fetal liver
are transported across the trophoblast epithelium from the
fetal to the maternal circulation. On a functional level, bile
salt uptake across the basolateral (fetal facing) membrane is
Na+-independent and thus could be Oatp/OATP-mediated
[19]. Furthermore, during pregnancy the placenta is a major
source of steroid hormones that are transported as sulfate
conjugates (e.g. dehydroepiandrosterone-sulfate (DHEAS),
pregnenolone sulfate). These sulfate conjugates are organic
anions and thus (potential) substrates of several Oatps/
OATPs [20]. At the RNA level, several Oatps/OATPs have
been localized to the placenta including Oatp9 and Oatp12
in the rat [92], and OATP-B, OATP-D and OATP-E in man
[4]. At the protein level, so far only OATP-B has been
detected in the trophoblast at the basal membranes where it
may play a role in transporting natural substrates (e.g.
steroid hormone conjugates) from the fetal circulation into
the trophoblast [20]. However, since OATP-B has a narrow
substrate specificity and does not transport bile salts [5],
additional (not yet identified) transport systems are probably
responsible for the elimination of bile acids and other
organic anions from the fetal circulation.
4.3.5. Eye
Rat Oatp2 and Oatp3 have been cloned, besides from
brain [40] and intestine [57], also from a retina cDNA
library [53]. Recently, using a specific antibody, Oatp2
could be localized to the retinal pigment epithelium, which
plays a vital role in the maintenance and function of
photoreceptors [93]. Oatp2 is expressed in the apical mem-
brane of this epithelium where it could be involved in the
transport of retinoids into and out of retinal pigment
epithelial cells.
The ciliary epithelium with its pigmented and non-
pigmented cell layers forms the barrier between the eye
(aqueous humor) and the rest of the body (blood) similar to
the BBB. Multispecific organic anion transport systems
have been suggested to be present in this epithelium for a
long time and indeed, preliminary data from our lab indicate
that several Oatps/OATPs are expressed in the nonpig-
mented ciliary epithelium of the rat (Oatp2 and Oatp4)
and the human eye (OATP-A, OATP-B, OATP-D and
OATP-E) (Gao and Meier, unpublished) where they might
be involved in maintaining the homeostasis of the aqueous
humor.
5. Regulation of Oatps/OATPs
5.1. Ontogenic expression
Several groups have studied ontogenic expression of
Oatps/OATPs in developing rat liver. In contrast to the
major bile salt transporters Ntcp and the bile salt export
pump Bsep, which were expressed around birth, significant
expression of Oatp1, Oatp2 and Oatp4 could only be
detected on the protein level during the first four weeks
after birth [94]. Similar results were also obtained on the
mRNA levels for rat liver Oatp2 and Oatp4 [79,95]. In
contrast, in the choroid plexus Oatp1 was detected already
at birth [88]. However, since the antibody used also
recognizes Oatp3, it cannot be excluded that the obtained
signal was actually due to Oatp3 expression (see above).
Using real-time PCR, several Oatps could be detected at
very low levels during late pregnancy. At birth, the
expression levels increased to 15% of adult levels for
Oatp1, to 0.05% for Oatp2, to 30% for Oatp4 and to
20% for Oatp9 [92]. Based on Northern blot analysis,
Oatp5 expression in the kidney was similarly to Oatp
expression in the liver detected only late during develop-
ment and could not be seen during the first 3 weeks after
birth [96]. Hence, in general, Oatps are expressed rather
late during rat liver development, indicating that they play
no major role in the development of the enterohepatic
circulation of bile salts.
5.2. Gender differences
Regulation of Oatp1 expression and function occurs at
transcriptional and post-transcriptional levels and is, at least
in part, tissue-specific. Thus, while in the kidney Oatp1
expression is stimulated by testosterone and inhibited by
estrogens, hepatic Oatp1 expression is not influenced by sex
hormones [91,97,98]. As a consequence, kidney Oatp1 is
considerably less abundantly expressed in female as com-
pared to male rats [98]. This gender difference in the renal
expression of apical Oatp1 is associated with increased
urinary excretion of estradiol-17h-D-glucuronide in female
as compared to male rats [91]. Whether expression of other
Oatps/OATPs is also affected by sex hormones remains to
be determined.
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5.3. Transcriptional regulation
Transcriptional regulation has so far been studied for
only a few Oatps/OATPs. In the rat, Oatp2 gene expression
is induced by phenobarbital [99] and pregnenolone-16a-
carbonitrile (PCN), a well-known inducer of cytochrome
P450 enzymes of the 3A family [100,101]. The mechanism
of PCN induction has been investigated in detail and several
pregnane X receptor (PXR) response elements have been
identified on the rat Oatp2 promoter [102]. Since lithocholic
acid, a cholestatic secondary bile acid formed in the intes-
tine by bacterial 7a-dehydroxylation of chenodeoxycholic
acid, is an endogenous ligand of PXR, concomitant PXR-
dependent up-regulation of Oatp2 (uptake) and CYP3A
(hydroxylation) represents an important constitutive re-
sponse in the hepatic detoxification of both cholestatic bile
salts and xenobiotic chemicals [101,103]. Hepatic expres-
sion of the human OATP-C gene has been shown to be
dependent on the liver-enriched transcription factor HNF-1a
[104]. Similarly, hepatic OATP8 expression is dependent on
HNF-1a [104] but, in addition, can be influenced by the bile
acid nuclear receptor FXR/BAR [105]. Whether human
liver OATPs can also be regulated by the xenobiotic
receptor PXR remains to be investigated.
5.4. Post-transcriptional regulation
On the protein level, functional regulation of Oatps has
been demonstrated for rat Oatp1 and Oatp2 [106,107].
Functional down-regulation of Oatp1 can occur via serine
phosphorylation by extracellular ATP [106]. In addition,
protein kinase C activation leads to decreased transport of
estrone-3-sulfate in Oatp1 expressing X. laevis oocytes
[107]. Hence, phosphorylated Oatp1 can lose its transport
activity without leaving the cell surface, indicating that the
phosphorylation state of membrane-associated Oatp1 must
be considered when assessing its functional alterations in
pathological states. Similarly, protein kinase C activators
suppress Oatp2-mediated digoxin transport in X. laevis
oocytes, demonstrating that also Oatp2 is regulated at the
protein level [107].
6. Expression and function in disease and disease models
So far no Oatp knockout mice have been generated.
However, Oatp expression has been investigated in several
knockout mouse models such as the HNF-1a- [108] and
HNF4a- [109] deficient mice, where all tested liver Oatps
are down-regulated, suggesting further an important role for
these two transcription factors in basal Oatp expression in
the liver. Furthermore, in mice with disrupted bile acid
receptor FXR/BAR, cholate feeding was associated with
increased Oatp1 expression [110]. Whether this negative
feedback regulation of Oatp1 by FXR/BAR occurs via
inhibition of the retinoid X receptor (RXR) and retinoic
acid receptor (RAR) heterodimer RXR:RAR or by the FXR/
BAR-dependent small heterodimer partner 1 (SHP-1) [111]
is not yet known. In PXR-deficient mice, basal Oatp2
expression was not changed but could not be induced
anymore by PCN (see above [101]).
Although several polymorphisms that affect substrate
transport mediated by the human OATP-C and OATP-B
have been identified [112,113], so far no evidence exists that
impaired Oatp/OATP function would cause a known dis-
ease. However, in several models of cholestatic liver dis-
eases such as endotoxin treatment (for sepsis-induced
cholestasis), ethinyl estradiol treatment (for cholestasis of
pregnancy) and bile duct ligation (for extrahepatic biliary
obstructions), expression of hepatocellular Oatps was down-
regulated [3,114]. Furthermore, cholate feeding of mice
resulted in down-regulation of Oatp1 mRNA expression
by about 25% and protein expression by 90%. Oatp4
mRNA expression was down-regulated by 55% [115].
Following partial hepatectomy, expression of rat Oatp1
declined rapidly to about 50% within 2 days and recovered
to normal levels at 4 days, while Oatp2 was maximally
down-regulated between days 4 and 7 and returned to
almost normal levels by 14 days [116]. In an animal model
of primary sclerosing cholangitis (PSC), Oatp1 and Oatp2
protein levels were 22% and 21% of controls, respectively,
while Oatp4 remained unchanged [117]. Similarly, in
patients with PSC, OATP-C mRNA levels are decreased
to f 50% as compared to control livers [118]. Hence,
during cholestasis and massive liver regeneration, down-
regulation of basolateral expression of hepatocellular Oatps
provides an explanation, at least in part, for the functional
transport defects associated with these pathological condi-
tions.
7. Suggestion for new classification and nomenclature
As repeatedly indicated in the previous sections, the
rapid independent identification of new Oatps/OATPs has
led to a proliferation of different names for identical proteins
(see Table 1). Since membrane transporters are generally
named according to their function, and since polytopic
expression of any Oatp/OATP in various organs cannot be
excluded until all tissues of the body will have been
examined, an organ specific nomenclature such as ‘‘liver
specific transporter (LST)’’ should be avoided as illustrated
with LST-2, which is also abundantly expressed in cancers
of several organs [73] and thus is not a liver specific
transporter. Furthermore, the human OATP2 has only a
46% amino acid sequence identity to the previously cloned
rat Oatp2 (Table 2), and therefore the two proteins do not
represent orthologous gene products. True orthologous gene
products have so far been identified in OATP families 2, 3
and 4 (Fig. 4). In order to avoid false associations of non-
orthologous gene products between species and to avoid
confusion in the future scientific discussions, clearly defined
B. Hagenbuch, P.J. Meier / Biochimica et Biophysica Acta 1609 (2003) 1–18 13
distinct names should be given to different gene products. In
this regard the provisional alphabetic ordering of the human
OATPs (i.e. OATP-A, OATP-B, OATP-C, etc.) is advanta-
geous, since it does not overlap with the previously estab-
lished continuous numbering of non-orthologous rat Oatps.
However, an alphabetic gene nomenclature is unusual since
the general rule is the continuous and species independent
numbering of orthologous gene products. Therefore, alpha-
betic ordering of human OATPs can only provisionally be
used until sequencing of the human, mouse and rat genomes
will have been completed and all Oatp/OATP orthologous
genes will have been identified in these species.
The so far used classification system, based on the rules
of the human and mouse/rat gene nomenclature committees
(SLC21A/Slc21a), unfortunately does not permit an
unequivocal and species independent identification of the
various Oatp/OATP genes. It neither allows the sub-classi-
fication of individual transporter superfamilies according to
the well-established rules of, for example, the cytochrome
P450 superfamily system [16] since it treats all solute
carriers as only one superfamily. Therefore, a classification
and nomenclature system is required that is based on
divergent evolution and defines an OATP superfamily that
is divided into families, subfamilies and individual gene
products according to the degree of amino acid sequence
identities and evolutionary relationships. Such a system has
been proven to be extremely helpful and convenient for the
classification of the cytochrome P450 and other drug-
metabolizing enzyme superfamilies [14–16], and could be
implemented easily also for the Oatps/OATPs and possibly
other polyspecific transporter families. It could well replace
the current SLC-classification once sequencing of the
human, mouse and rat genomes will have been completed.
The wide variation of the Oatp/OATP amino acid
sequence identities (Table 2) results in a clear clustering
of the individual proteins into families and subfamilies as is
visualized using a phylogenetic tree (Fig. 4). Following the
guidelines of the nomenclature committees of the drug-
metabolizing enzymes [14–16], we therefore classified the
various Oatps/OATPs into different gene families with less
than 40% amino acid sequence identities to members of any
other family and named them OATP1, OATP2, OATP3,
OATP4 and OATP5 (see above and Fig. 4). Oatps/OATPs
within the same family share more than 40% amino acid
sequence identities among each other (Table 2, Fig. 4).
Individual subfamilies include Oatps/OATPs with amino
acid sequence identities of more than 60% and are desig-
nated with letters (e.g. OATP1A, OATP1B etc.; Fig. 4). If
Fig. 5. Classification and suggested new nomenclature of 41 members of the OATP gene superfamily. Individual genes are categorized into families and
subfamilies based on their amino acid sequence identities of 40–60% and z 60%, respectively. The phylogram was calculated using the GCG programs PILEUP,
DISTANCES and GROWTREE and visualized using the program TreeView [17]. Where available the current gene symbols are given. The ‘‘Current Nomenclature’’
column lists the currently used names of the known Oatp/OATPs and the protein accession number for the other proteins.
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there are several individual genes within the same subfam-
ily, additional continuous Arabic numbering based on the
chronology of gene identification can be used. Following
these rules, the OATP superfamily can presently be divided
into 12 families with a total number of 41 genes. In addition,
screening the EST databases, we identified related protein
fragments (amino acid identities 43–98%) from numerous
species including, e.g. sea urchin (Strongylocentrotus pur-
puratus), sea squirt (Ciona intestinalis), honey bee (Apis
mellifera), zebrafish (Danio rerio), catfish (Ictalulurs punc-
tatus), frogs (Xenopus laevis and Silurana tropicalis),
chicken (Gallus gallus) and pig (Sus scorfa). They were
not yet included because they do not encode full-length
proteins. However, this emphasizes again the need for the
suggested new classification and nomenclature system, illus-
trated in Fig. 5, which can identify unambiguously all
present and future members of the superfamily by assigning
(1) the superfamily designation OATP (human members) or
Oatp (animal species), (2) the family number, (3) the sub-
family letter (capital letters for human members, small letters
for animal members), and (4) continuous Arabic numbering
according to the chronology of gene identification. We
suggest that the phylogenetically based new classification
and nomenclature system should replace the chaotic and
partially erroneous current nomenclature (Table 1, Fig. 5) in
the near future, since this suggested new classification and
nomenclature system takes into account the molecular and
phylogenetic relationships between individual genes, allows
to differentiate between orthologous human and rodent
proteins (OATP1A as compared to Oatp1a), is easy to follow,
and provides an unambiguous open-ended nomenclature for
all members of the OATP superfamily.
8. Conclusions and perspectives
There are currently 31 mammalian members of the OATP
superfamily. Many of these proteins are multispecific and
transport a broad range of amphipathic endo- and xeno-
biotics. Their expression in multiple tissues including the
liver, the kidney, the small intestine and the BBB puts them
into a strategic position for absorption, distribution and
excretion of drugs and toxins. Thus, Oatps/OATPs are
important transporters of the overall body detoxification
system. Furthermore, the predominant or even exclusive
localization of certain Oatps/OATPs in some tissues (e.g.
‘‘liver-specific’’ Oatp4, OATP-C and OATP8; restricted
expression of OATP-F in brain and testis) indicates that
selective transporters might be suitable for tissue-specific
drug targeting.
The OATP superfamily is rapidly growing since new
members continue to be discovered through genome-wide
sequencing projects such as the ‘‘Fugu Genome Project’’.
Further members are expected to be identified during geno-
mic sequencing of additional species including cat, dog and
bovine genomes.
Besides the members of the OATP superfamily, there are
additional organic anion transporters (OATs) and OCTs that
are classified within the solute carrier family 22A [42,43].
These transporters are predominantly expressed in the
kidney (basolateral membrane of proximal tubular epithelial
cells) where they are involved in the renal excretion of small
hydrophilic organic anions (OATs) and organic cations
(OCTs). Although a few typical Oatp/OATP compounds
are also substrates of certain OATs (e.g. estrone-3-sulfate,
ochratoxin A) and OCTs (e.g. N-methyl-quinidine), the
distinct substrate preferences of Oatps/OATPs and OATs/
OCTs complement each other. Thus, while Oatps/OATPs
can account for the hepatic clearance of larger amphipathic
albumin-bound organic compounds, OATs/OCTs are
responsible for active renal excretion of small hydrophilic
organic substances. Hence, Oatps/OATPs and OATs/OCTs
represent important drug carriers with complementary trans-
port functions that have to be taken into account for rational
drug design and targeting.
Although rapid progress has been made in the identifi-
cation of individual members of the OATP superfamily,
numerous questions remain unanswered and require more
detailed investigations in the near future. They relate espe-
cially to (1) the elucidation of the exact tissue expression of
individual Oatps/OATPs under physiologic and various
pathophysiologic (disease dependent altered expression?)
conditions, (2) the more detailed characterization of the
driving force(s) involved in Oatp/OATP-mediated substrate
transport, (3) a more detailed understanding of the molec-
ular basis of the broad substrate specificity of most Oatps/
OATPs through detailed structure/function, site-directed
mutagenesis and crystallization studies in isolated proteins,
(4) the development of specific inhibitors for individual
Oatps/OATPs, (5) investigation of the transcriptional and
post-transcriptional regulation of individual transporter
expression, (6) elucidation of functionally important inter-
actions of Oatps/OATPs with cytosolic and other membrane
proteins, (7) identification of gene polymorphisms and
elucidation of their functional consequences for overall drug
absorption and disposition (genotype/phenotype correla-
tion), and (8) elucidation of the overall significance of
individual Oatps/OATPs for physiology and pathophysiol-
ogy through generation of gene knock-out models in cases
where true Oatp/OATP homologues have been identified
and/or the use of model organisms such as C. elegans and
D. melanogaster.
Obviously a standardized and unified nomenclature sys-
tem is an urgent requirement to perform successfully the
abovementioned future studies and to avoid further misun-
derstandings between various research groups. The urgency
of this step is underlined by several recent examples of
erroneous assignments of functional properties of rat Oatp2
to human OATP2 (OATP-C) [6] and of rat Oatp2 to OAT2
[119]. Furthermore, an organ-specific nomenclature has
been used for newly identified Oatps/OATPs despite the
fact that the respective transporter is also expressed in other
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tissues [73] and/or probably represents a true orthologue of a
multilocalized transporter in another species (e.g. z 80%
amino acid identities between the bovine ‘‘liver-specific
organic anion transporter’’ (accession number AY052775)
and human OATP-A). In order to avoid further confusions
and to help young investigators in the field, we propose the
implementation of a new phylogenetically based, species
independent and unambiguous open-ended nomenclature for
all members of the OATP superfamily that has been adapted
from the successful classification system of the cytochrome
P450 superfamily (see Fig. 5). Our proposed new classifi-
cation and nomenclature system for the OATP superfamily
is in full agreement with the recent nomenclature guidelines
of the Human Nomenclature Committee [120].
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